ROME Therapeutics
- Founded: 2019
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: RD
- Therapy area: Autoimmune disease
- Drug types: IMM, ONC
- Lead product: Undisclosed
- Product link: https://rometx.com/the-dark-genome/
- Funding: $77M B Sep 2021; $50M A Apr 2020
- Investors: GV, Arch Venture Partners, Partners Innovation Fund
rometx.com linkedin.com job board
Short description:
Drugging Junk DNA
Drug notes:
4 additional undisclosed programs RD oncology
Long description:
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by characterizing the dark genome. The dark genome refers to the 98% of the human genome that does not code for protein and instead consists of repetitive elements such as ancient retroviral elements. While in healthy cells these viral repeats are silenced, evidence shows their activation in diseased or injured cells. ROME is developing therapies that can prevent this activation to reduce inflammation observed in disease. Their lead program is an inhibitor of LINE-1 reverse transcriptase, a protein that is expressed when these viral elements get activated. This program is in early clinical development for skin diseases such as dermatomyositis.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com